Multiple Mutations Contribute to the Oncogenicity of the Retroviral Oncoprotein V-Rel
Overview
Authors
Affiliations
The avian Rev-T retrovirus encodes the v-Rel oncoprotein, which is a member of the Rel/NF-kappaB transcription factor family. v-Rel induces a rapidly fatal lymphoma/leukemia in young birds, and v-Rel can transform and immortalize a variety of avian cell types in vitro. Although Rel/NF-kappaB transcription factors have been associated with oncogenesis in mammals, v-Rel is the only member of this family that is frankly oncogenic in animal model systems. The potent oncogenicity of v-Rel is the consequence of a number of mutations that have altered its activity and regulation: for example, certain mutations decrease its ability to be regulated by IkappaBalpha, change its DNA-binding site specificity, and endow it with new transactivation properties. The study of v-Rel will continue to increase our knowledge of how cellular Rel proteins contribute to oncogenesis by affecting cell growth, altering cell-cycle regulation, and blocking apoptosis. This review will discuss biological and molecular activities of v-Rel, with particular attention to how these activities relate to structure - function aspects of the Rel/NF-kappaB transcription factors.
Han W, Xiong W, Sun W, Liu W, Zhang Y, Li C Cell Transplant. 2024; 33:9636897241290910.
PMID: 39466658 PMC: 11528794. DOI: 10.1177/09636897241290910.
Overexpression of TRIM44 mediates the NF-κB pathway to promote the progression of ovarian cancer.
Yu Y, Li S, Sun J, Wang Y, Xie L, Guo Y Genes Genomics. 2024; 46(6):689-699.
PMID: 38691326 DOI: 10.1007/s13258-024-01517-7.
Turek I, Nguyen T, Galea C, Abad I, Freihat L, Manallack D Int J Mol Sci. 2023; 24(10).
PMID: 37239919 PMC: 10217915. DOI: 10.3390/ijms24108572.
Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.
Vitali L, Merlini A, Galvagno F, Proment A, Sangiolo D Biomedicines. 2022; 10(10).
PMID: 36289890 PMC: 9599827. DOI: 10.3390/biomedicines10102628.
NF-κB and Human Cancer: What Have We Learned over the Past 35 Years?.
Gilmore T Biomedicines. 2021; 9(8).
PMID: 34440093 PMC: 8389606. DOI: 10.3390/biomedicines9080889.